Begelomab Biosimilar - Research Grade

Human

DPP4

>1mg/ml

IgG2b - kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

P27487

Blue ice

This product is a research-grade biosimilar of Begelomab, supplied as an unconjugated, non-therapeutic analog of the originator antibody for research use only. It is built around the target dipeptidyl peptidase-4 (DPP4, also known as CD26; UniProt P27487) and reproduces the binding specificity of the originator molecule rather than being defined by a hybridoma clone. The originator, Begelomab, is a murine IgG2b monoclonal antibody directed against human DPP4/CD26, and it has been investigated as an immunomodulatory agent, notably in the context of steroid-refractory acute graft-versus-host disease and severe inflammatory myopathy, where CD26-bearing activated T cells are relevant. This biosimilar reagent is intended to serve as a consistent, well-characterized binding reference for functional and in-vitro studies, comparability assessments, and assay development. It is manufactured to research-grade endotoxin specifications and offered in bulk quantities suitable for laboratory workflows. It is not a clinical drug and is not intended for therapeutic or diagnostic use in humans or animals. Because the target is a human antigen, the reagent is used primarily in cell-based and biochemical systems. DPP4 (CD26) is a type II transmembrane serine exopeptidase that also exists in a soluble circulating form. Its extracellular domain cleaves N-terminal dipeptides from peptides with proline or alanine at the second position, thereby regulating the activity of incretins such as GLP-1 and GIP, as well as chemokines and neuropeptides. Beyond its enzymatic role, CD26 is a costimulatory molecule on T lymphocytes, associating with adenosine deaminase and interacting with caveolin-1 to influence T-cell activation, proliferation, and cytokine production. It is expressed on activated T cells, epithelial and endothelial cells, and various tumors. Because of its dual enzymatic and immunoregulatory functions, DPP4/CD26 is studied in metabolic disease, immunology, transplantation, and oncology, making antibodies against it useful tools for probing T-cell biology and CD26-dependent signaling.

ADABP, Adenosine deaminase complexing protein 2, ADCP-2, Dipeptidyl peptidase IV, DPP IV, T-cell activation antigen CD26, TP103, Dipeptidyl peptidase 4, CD26

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Q: Is the Begelomab biosimilar available in gram quantities?

A: Yes — it is manufactured in scalable milligram to gram quantities to support bulk and high-throughput preclinical experiments.

Q: Is this research-grade Begelomab biosimilar suitable for in vivo studies?

A: Yes, it is supplied in a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Begelomab biosimilar target?

A: It is an unconjugated, non-therapeutic research analog of Begelomab that binds DPP4; for research use only.